liquiritigenin has been researched along with Angiogenesis, Pathologic in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cai, YQ; Liu, CW; Luo, K; Wang, Y; Xie, SR | 1 |
Cai, Y; Liu, Y; Luo, K; Wang, Y; Xie, S | 1 |
2 other study(ies) available for liquiritigenin and Angiogenesis, Pathologic
Article | Year |
---|---|
Liquiritigenin inhibits serum-induced HIF-1α and VEGF expression via the AKT/mTOR-p70S6K signalling pathway in HeLa cells.
Topics: Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Flavanones; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Biosynthesis; Protein Stability; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; Serum; Signal Transduction; TOR Serine-Threonine Kinases; Transcriptional Activation; Vascular Endothelial Growth Factor A | 2012 |
Liquiritigenin inhibits tumor growth and vascularization in a mouse model of HeLa cells.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Proliferation; Flavanones; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Neoplasms; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |